GenSight’s management team will host a webcast on Wednesday July 7, 2021 from 8:30 am to 9:30 am CEST in French and dedicated to retail investors about the Topline results from REFLECT Phase III Clinical Trial of LUMEVOQ® in the treatment of Leber Hereditary Optic Neuropathy (LHON) that GenSight reported on June 30, 2021..
Dr. José-Alain Sahel will attend and be available for questions.
Wednesday July 7, 2021
- 8:30 – 9:30 am CEST
- The event will be webcast live in French at https://bit.ly/36fQ9yO
You will need to register in advance to get access to both webcasts. For those unable to attend the live broadcast, a recording will be accessible using the same links.